CX-5461 clinical trials

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

This study looks at a new drug, CX-5461, for advanced solid tumours in patients with specific gene changes (like BRCA1/2). It aims to find the safest dose and see if the drug helps, also checking quality of life.